Clinical Trial Update: Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma [Phase 2]

View source ↗

Summary

Phase II efficacy study of an aerosolized recombinant human IL-4 receptor for asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Hypersensitivity

Drugs mentioned

• Aerosolized Recombinant Human IL-4 Receptor (recombinant human IL-4 receptor)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Asthma, Hypersensitivity | Phase 2 | Status: COMPLETED